MA52076A - Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 - Google Patents

Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1

Info

Publication number
MA52076A
MA52076A MA052076A MA52076A MA52076A MA 52076 A MA52076 A MA 52076A MA 052076 A MA052076 A MA 052076A MA 52076 A MA52076 A MA 52076A MA 52076 A MA52076 A MA 52076A
Authority
MA
Morocco
Prior art keywords
antibodies
combination
Prior art date
Application number
MA052076A
Other languages
English (en)
Inventor
Michael Dewain Kalos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA52076A publication Critical patent/MA52076A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
MA052076A 2018-03-23 2019-03-15 Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 MA52076A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862647046P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
MA52076A true MA52076A (fr) 2021-01-27

Family

ID=65952175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052076A MA52076A (fr) 2018-03-23 2019-03-15 Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1

Country Status (12)

Country Link
US (2) US20210054089A1 (fr)
EP (1) EP3768712A1 (fr)
JP (1) JP7059389B2 (fr)
KR (3) KR20240017090A (fr)
CN (1) CN112041346B (fr)
AU (1) AU2019237977B2 (fr)
CA (1) CA3094998C (fr)
EA (1) EA202092262A1 (fr)
IL (1) IL277511A (fr)
MA (1) MA52076A (fr)
MX (1) MX2020009864A (fr)
WO (1) WO2019182879A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432046B1 (ko) 2018-03-23 2022-08-12 일라이 릴리 앤드 캄파니 항-pd-l1 항체와의 조합을 위한 항-cd137 항체
CN114269788B (zh) * 2019-11-13 2024-08-20 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子及其应用
US12331116B2 (en) * 2021-01-11 2025-06-17 Eutilex Co., Ltd. Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SG10201912092VA (en) * 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
CA2935423C (fr) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Molecules d'anticorps anti-pd-1 et leurs utilisations
ES2783026T3 (es) * 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
US10392438B2 (en) * 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CN112546238A (zh) * 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
JP6743320B1 (ja) * 2017-08-01 2020-08-19 イーライ リリー アンド カンパニー 抗ｃｄ１３７抗体
KR102432046B1 (ko) * 2018-03-23 2022-08-12 일라이 릴리 앤드 캄파니 항-pd-l1 항체와의 조합을 위한 항-cd137 항체

Also Published As

Publication number Publication date
JP2021516251A (ja) 2021-07-01
CA3094998C (fr) 2023-05-09
MX2020009864A (es) 2021-01-08
IL277511A (en) 2020-11-30
KR20200134288A (ko) 2020-12-01
EA202092262A1 (ru) 2021-01-14
AU2019237977A1 (en) 2022-01-20
WO2019182879A1 (fr) 2019-09-26
US20250333525A1 (en) 2025-10-30
KR20250038810A (ko) 2025-03-19
AU2019237977B2 (en) 2026-03-26
CN112041346A (zh) 2020-12-04
EP3768712A1 (fr) 2021-01-27
US20210054089A1 (en) 2021-02-25
NZ768428A (en) 2024-08-30
CA3094998A1 (fr) 2019-09-26
CN112041346B (zh) 2024-10-22
KR20240017090A (ko) 2024-02-06
JP7059389B2 (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
MA48604A (fr) Anticorps anti-tim-3 pour une combinaison avec des anticorps anti-pd-1
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA52884A (fr) Anticorps anti-il-11
MA52366A (fr) Anticorps anti-tl1a optimisés
MA53434A (fr) Anticorps anti-tigit
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
FR25C1022I2 (fr) Anticorps anti-pd-1
MA53905A (fr) Anticorps stabilisant trem2
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
MA49749A (fr) Anticorps anti-cd137
MA47456A (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
MA46057A (fr) Anticorps anti-ctla4
EP3648801A4 (fr) Compositions de dota-haptène pour une radioimmunothérapie préciblée par un anticorps bispécifique antigène anti-dota/anti-tumoral
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3885367A4 (fr) Anticorps bispécifique anti-her2/pd1
EP3247718A4 (fr) Modulation de variants de charge dans une composition d'anticorps monoclonaux
MA52545A (fr) Anticorps pour radionucléides chélatés
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3746120A4 (fr) Anticorps anti-pd-1
MA52152A (fr) Anticorps
EP3752536A4 (fr) Anticorps anti-her2
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3831851A4 (fr) Anticorps anti-btla